# A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones

> **NCT04521361** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 46 (actual)

## Conditions studied

- Bone Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Radium-223 dichloride (Xofigo, BAY88-8223)

## Key facts

- **NCT ID:** NCT04521361
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-16
- **Primary completion:** 2023-10-10
- **Final completion:** 2025-08-27
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04521361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04521361, "A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04521361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*